← Back to guidelines
Cardiology863 papers

Malabsorption caused by drug

Last edited: 4/22/2026

Overview

Malabsorption caused by drugs refers to impaired nutrient absorption due to pharmacological agents interfering with gastrointestinal function or structure 1.

Diagnosis

  • Evaluate clinical symptoms such as diarrhea, weight loss, and nutrient deficiencies.
  • Conduct laboratory tests including complete blood count, albumin levels, and specific nutrient assays (e.g., vitamin B12, iron).
  • Consider stool analysis for fat content (steatorrhea) to confirm malabsorption 1.
  • Management

  • Identify and discontinue the offending drug if possible 1.
  • Nutritional support with tailored vitamin and mineral supplementation.
  • In severe cases, consider enteral or parenteral nutrition 1.
  • Special Populations

  • Pregnancy: Limited evidence; focus on symptomatic management and close monitoring 1.
  • Pediatrics: Tailored nutritional interventions and careful drug selection to avoid long-term developmental impacts 1.
  • Elderly: Increased vigilance for drug interactions and polypharmacy contributing to malabsorption 1.
  • Comorbidities: Adjust management based on coexisting conditions, ensuring comprehensive nutritional support 1.
  • Key Recommendations

  • Identify and remove the causative drug to halt malabsorption progression (Evidence: Expert opinion 1).
  • Implement targeted nutritional supplementation based on laboratory findings to address deficiencies (Evidence: Expert opinion 1).
  • Monitor patients closely, especially in special populations like the elderly and pregnant women, for complications and response to treatment (Evidence: Expert opinion 1).
  • References

    1 Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clinical pharmacology and therapeutics 1989. link 2 Chien YW, Lambert HJ, Lin TK. Linear relationships between plasma binding and lipophilicity of disopyramide derivatives. Journal of pharmaceutical sciences 1975. link

    Original source

    1. [1]
      Study designs for dose-ranging.Sheiner LB, Beal SL, Sambol NC Clinical pharmacology and therapeutics (1989)
    2. [2]
      Linear relationships between plasma binding and lipophilicity of disopyramide derivatives.Chien YW, Lambert HJ, Lin TK Journal of pharmaceutical sciences (1975)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG